BioCentury | Jan 13, 2020
Clinical News

Adaptimmune rises on early promise for SPEAR TCR cell therapies in solid tumors

Cancer cell therapy play Adaptimmune gained $2.66 (200%) to $3.99 on Monday after announcing a new set of data for its SPEAR T cell therapies in four different solid tumor indications. The announcement by Adaptimmune...
BioCentury | Oct 19, 2019
Product Development

How GSK has rebuilt its oncology pipeline from the ground up

...the infrastructure to create a broader pipeline. GSK acquired NY-ESO T cell receptor (TCR) therapy GSK3377794...
BioCentury | Oct 9, 2019
Company News

GSK partners with Lyell to bring gene, cell therapies into solid tumors

...therapy, GSK3377794, before applying it to other assets in its cell and gene therapy pipeline. GSK3377794...
...antigen 2; NY-ESO-1 (CTAG1B) - Cancer/testis antigen 1B Elizabeth S. Eaton, Staff Writer ADAP NY-ESO TCR, NY-ESO SPEAR T-cell therapy (GSK3377794, enhanced T-cell therapy targeting NY-ESO-1, Enhanced TCR therapy targeting NY-ESO-1) Lyell...
BioCentury | Dec 21, 2018
Product R&D

Cell therapies seek solid ground

...explains complete responses of patients with synovial sarcoma and multiple myeloma (MM) to his company’s NY-ESO SPEAR T-cell therapy...
...which express TCRs against NY-ESO-1, in 2017 and is developing the product under the designation GSK3377794...
...factor β TLR - Toll-like receptor TTN - Titin Emily Cukier, Senior Writer ADAP NY-ESO TCR, NY-ESO SPEAR T-cell therapy (GSK3377794, enhanced T-cell therapy targeting NY-ESO-1, Enhanced TCR therapy targeting NY-ESO-1) Adaptimmune...
BioCentury | Jul 27, 2018
Company News

GSK, 23andMe partner on target, drug discovery

...focus on areas of biology that open up multiple indications. Barron highlighted immune-modulating clinical assets GSK3377794...
...2021-2026. Functional genomics, machine learning and cell therapy constitute priority technologies for research, he added. GSK3377794...
BioCentury | Jul 25, 2018
Company News

GSK's near-term R&D prospects include an ADC as it pivots to immunology

...focus on areas of biology that open up multiple indications. Barron highlighted immune-modulating clinical assets GSK3377794...
...2021-2026. Functional genomics, machine learning and cell therapy constitute priority technologies for research, he added. GSK3377794...
BioCentury | Apr 13, 2018
Company News

Orchard gains GSK's rare disease gene therapy portfolio

...U.K. Orchard Therapeutics Ltd., London, U.K. Business: Gene/Cell therapy Jennie Walters 2696274, GSK2696274 2696275, GSK2696275 ADAP NY-ESO TCR, NY-ESO SPEAR T-cell therapy (GSK3377794, enhanced T-cell therapy targeting NY-ESO-1, Enhanced TCR therapy targeting NY-ESO-1) EFS...
BioCentury | Apr 12, 2018
Company News

Orchard gains GSK's rare disease gene therapy portfolio

GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) said it will divest its rare disease gene therapy portfolio, including Strimvelis, to Orchard Therapeutics Ltd. (London, U.K.). GSK will be eligible to receive undisclosed commercial milestones and royalties. The pharma...
BioCentury | Mar 16, 2018
Clinical News

Adaptimmune reports early Phase I/II liposarcoma data for NY-ESO SPEAR T cells

...Abingdon, U.K. GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), London, U.K. Product: NY-ESO SPEAR T cell therapy (ADAP NY-ESO TCR, GSK3377794...
...overall survival and safety Status: Phase I/II data Milestone: NA Jaime De Leon ADAP NY-ESO TCR, NY-ESO SPEAR T-cell therapy (GSK3377794, enhanced T-cell therapy targeting NY-ESO-1, Enhanced TCR therapy targeting NY-ESO-1) Adaptimmune...
BioCentury | Mar 15, 2018
Clinical News

Adaptimmune gains on early liposarcoma data for NY-ESO SPEAR T cells

...lung cancer (NSCLC) (see BioCentury Extra, Sept. 7, 2017) . Jaime De Leon ADAP NY-ESO TCR, NY-ESO SPEAR T-cell therapy (GSK3377794, enhanced T-cell therapy targeting NY-ESO-1, Enhanced TCR therapy targeting NY-ESO-1) Adaptimmune...
Items per page:
1 - 10 of 31